NATHAN PUNWANI, MD

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

New patient office or other outpatient visit, 60-74 minutes

Administration of chemotherapy into vein, 1 hour or less

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Administration of chemotherapy into vein using push technique

Established patient office or other outpatient visit, 40-54 minutes

Hospital discharge day management, more than 30 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Leuprolide acetate (for depot suspension), 7.5 mg

Infusion into a vein for hydration, 31-60 minutes

Established patient office or other outpatient visit, 30-39 minutes

Injection, atezolizumab, 10 mg

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Administration of additional new drug or substance into vein using push technique

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Established patient office or other outpatient visit, 20-29 minutes

Injection, pembrolizumab, 1 mg

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg

Administration of chemotherapy into vein, each additional hour

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Established patient office or other outpatient visit, 10-19 minutes

Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Collection of blood sample from implanted device

Injection of additional new drug or substance into vein

Injection, nivolumab, 1 mg

Injection of drug or substance under skin or into muscle

Infusion into a vein for hydration, each additional hour

Application of on-body injector for under skin injection

Injection, denosumab, 1 mg

Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

Infusion, normal saline solution, sterile (500 ml = 1 unit)

Infusion, normal saline solution , 1000 cc

Injection, paclitaxel protein-bound particles, 1 mg

Injection, zoledronic acid, 1 mg

Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg

Unclassified drugs

Injection, diphenhydramine hcl, up to 50 mg

Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg

Injection, magnesium sulfate, per 500 mg

Injection, carboplatin, 50 mg

Injection, fluorouracil, 500 mg

Injection, cisplatin, powder or solution, 10 mg